Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166794/
Ha-Young Park, 1 Joo-Heon Park, 2 Myung-Geun Shin, 2 Seung Jung Han, 3 Yong-Sok Ji, 4 Hyung-Joo Oh, 1 Young-Chul Kim, 1 Taebum Lee, 5 Yoo-Duk Choi, 5 and In-Jae...
Conclusion: In this case report, we are reporting a rare case of ultra-late recurrence of NSCLC in a patient with choroidal metastasis. Furthermore, the diagnosis of NSCLC with RET fusion was based on liquid-based NGS rather than tissue-based biopsy. The patient showed a good response to selpercatinib, which supports the efficacy of...
Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe
Source : https://www.frontiersin.org/articles/10.3389/fonc.2023.1141314/full
The incidence of thyroid cancer is increasing worldwide with the disease burden in Europe second only to that in Asia. In the last several decades, molecular pathways central to the...
Conclusions: The molecular profiling of thyroid cancers and development of targeted therapies have revolutionised the therapeutic landscape for patients with advanced thyroid cancer. Additionally, updated guidelines for the genomic profiling of patients with advanced and progressive thyroid cancer will facilitate molecular-targeted treatment...
Clinical use of molecular data in thyroid nodules and cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37200449/
Over the past three decades, advances in the molecular genetics of thyroid cancer (TC) have been translated into diagnostic tests, prognostic markers and therapeutic agents. The main drivers in differentiated...
Relevance: This mini-review discusses the utilization of molecular data in the clinical management of patients with thyroid nodules and TC in these different clinical situations.
Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review
Source : https://tlcr.amegroups.com/article/view/73989/html
Lung cancer is the most common cause of cancer-related death in the world ( 1). Non-small cell lung cancer (NSCLC) is responsible for approximately 85% of lung cancer cases. Most...
Conclusions/Relevance: The non-Asian population were shown to be more likely to be treated with selpercatinib and pralsetinib for RET-rearranged NSCLC than the Asian population.
RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
Source : https://www.frontiersin.org/articles/10.3389/fonc.2023.1078076/full
Patients with metastatic pancreatic cancer have limited treatment options and a dismal prognosis. While RET fusion is rare (0.6%) in pancreatic cancer, the efficacy of RET-targeted treatment in patients with...
Conclusions/Relevance: To our knowledge, this is the first report on the clinical value of a single TRIM33-RET fusion in pancreatic cancer, which may benefit from the targeted therapy.